Isotonic Solution Administration Logistical Testing

Proportion of total intravenous isotonic crystalloid administered during admission to the intensive care unit that is 0.9% sodium chloride, censored at 30 days. The primary outcome was the proportion of intravenous isotonic crystalloid administered in the ICU that was saline. This was a continuous variable calculated for each patient as the volume of saline received divided by volume of saline received plus volume of balanced crystalloids received with a range from 0.0 (no saline received) to 1.0 (only saline received).

Proportion of total intravenous isotonic crystalloid administered during admission to the intensive care unit that is either Lactated ringers or Plasmalyte-A, censored at 30 days.

Total volume of intravenous fluid administration during admission to the intensive care unit, censored at 30 days

Total volume of intravenous isotonic crystalloid administration during admission to the intensive care unit, censored at 30 days

Total volume of intravenous colloid administration (excluding blood products) during admission to the intensive care unit, censored at 30 days

Total volume of packed red blood cells, platelets, and fresh frozen plasma administered during admission to the intensive care unit, censored at 30 days

highest serum chloride (mmol/L) during admission to the intensive care unit, censored at 30 days

Highest serum sodium concentration (mmol/L) during admission to the intensive care unit, censored at 30 days

Lowest serum bicarbonate concentration (mmol/L) during admission to the intensive care unit, censored at 30 days

Incidence of Major Adverse Kidney Events by 30 days -- a composite outcome defined as one or more of the following: death, new use of renal replacement therapy, or persistence of renal dysfunction at hospital discharge or at 30 days (defined as an increase in serum creatinine ≥ 200% from baseline)

Death prior to the earlier of hospital discharge or day 30

Receipt of new renal replacement therapy after the first study day, censored at 30 days

Persistence of renal dysfunction at hospital discharge or at 30 days (defined as an increase in serum creatinine ≥ 200% from baseline)

Number of contraindications to assigned study fluid identified by providers, censored at 30 days

Incidence of hyperchloremia defined as a serum chloride greater than or equal to 110 mmol/L

Incidence of severe hypochloremia defined as a serum chloride less than 90mmol/L

Increase in serum creatinine during hospitalization, censored at 30 days Change from baseline to highest value, median (IQR), mg/dl

Incidence of stage II or III acute kidney injury by Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury criteria, censored at 30 days

ICU-free days to 28 days after enrollment will be defined as the number of days alive and not admitted to an intensive care unit service after the patient's final discharge from the intensive care unit before 28 days. If the patient is admitted to an intensive care unit service at day 28 or dies prior to day 28, ICU-free days will be 0.

Ventilator-free days to day 28 will be defined as the number of days alive and with unassisted breathing to day 28 after enrollment, assuming a patient survives for at least two consecutive calendar days after initiating unassisted breathing and remains free of assisted breathing. If a patient returns to assisted breathing and subsequently achieves unassisted breathing prior to day 28, VFD will be counted from the end of the last period of assisted breathing to day 28. If the patient is receiving assisted ventilation at day 28 or dies prior to day 28, VFD will be 0.

Dialysis free survival to day 28 will be defined as the number of days alive and without dialysis receipt to day 28 after enrollment, assuming a patient survives for at least two consecutive calendar days after last receipt of dialysis and remains free of dialysis. If the patient is receiving dialysis at day 28 or dies prior to day 28, VFD will be 0.

Highest creatinine value in the first 30 days